Li Qin, Cong Yu-Long, Wang Bao-En, Jia Ji-Dong, Chen Yu, Zhang Fu-Kui, Ou Xiao-Juan, Wei Yu-Xiang, Ma Hong
Liver Research Center, Beijing Friendship Hospital Affiliated to Capital University of Medical Sciences, Beijing 100050, China.
Zhonghua Gan Zang Bing Za Zhi. 2005 Feb;13(2):128-31.
To determine which expression mode of prothrombin time (PT) might achieve PT standardization in patients with advanced liver diseases.
PT was measured with six thromboplastins with different ISI values in 16 severe chronic hepatitis patients, 50 decompensated liver cirrhosis patients and 30 patients on oral anticoagulation therapy. The results were expressed in PT (second), PTA (%), PTR and INR.
In chronic hepatitis patients, the means of the six group's PTAs ranged from 24% to 34%, while their upper limits ranged from 47% to 61%. The means of the INRs ranged from 2.55 to 5.13, while their upper limits ranged from 4.65 to 12.77. Through one-way ANOVA of repeated measures, PPTA (0.489) was > PINR (0.120). In patients with liver cirrhosis, the means of the PTA in six groups ranged from 50% to 59%, while their upper limits ranged from 82% to 90%. The means of the INR ranged from 1.40 to 1.80, while their upper limits ranged from 1.97 to 3.69. Through one-way ANOVA of repeated measures, PPTA (0.102) was > PINR (0.01). In patients on oral coagulation therapy, the means of PTA ranged from 26% to 37%, while their upper limits ranged from 39% to 49%. The means of INR ranged from 2.35 to 2.66, while their upper limits ranged from 3.16 to 4.26. Through one-way ANOVA of repeated measures, PPTA (0.01) was less than PINR (0.102). The correlation between the results detected by Neoplastine and by other reagents were analyzed. They correlated well with each other when PTA was used as the expression mode of PT in patients with advanced liver disease. But in patients on oral anticoagulation therapy, when only the INR was used as the expression mode of PT, the correlation was well with each other.
The use of INR provides inadequate standardization. Only when the PT is expressed in PTA, then it may provide a standardization mode in patients with advanced liver diseases.
确定凝血酶原时间（PT）的哪种表达模式可实现晚期肝病患者PT的标准化。
用六种国际敏感度指数（ISI）值不同的凝血活酶检测16例重度慢性肝炎患者、50例失代偿期肝硬化患者和30例接受口服抗凝治疗患者的PT。结果以PT（秒）、PTA（%）、PTR和INR表示。
在慢性肝炎患者中，六组PTA的均值为24%至34%，其上限为47%至61%。INR的均值为2.55至5.13，其上限为4.65至12.77。经重复测量的单因素方差分析，PPTA（0.489）大于PINR（0.120）。在肝硬化患者中，六组PTA的均值为50%至59%，其上限为82%至90%。INR的均值为1.40至1.80，其上限为1.97至3.69。经重复测量的单因素方差分析，PPTA（0.102）大于PINR（0.01）。在接受口服抗凝治疗的患者中，PTA的均值为26%至37%，其上限为39%至49%。INR的均值为2.35至2.66，其上限为3.16至4.26。经重复测量的单因素方差分析，PPTA（0.01）小于PINR（0.102）。分析了用Neoplastine试剂与其他试剂检测结果之间的相关性。在晚期肝病患者中，当以PTA作为PT的表达模式时，它们之间相关性良好。但在接受口服抗凝治疗的患者中，仅以INR作为PT的表达模式时，它们之间相关性良好。
使用INR提供的标准化不足。只有当PT以PTA表示时，才可能为晚期肝病患者提供一种标准化模式。
